Patents by Inventor Rama K. Narla

Rama K. Narla has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20140200207
    Abstract: Provided herein are Pyrrolopyrimidine Compounds having the following structure: wherein R1, R2, R3, and L are as defined herein, compositions comprising an effective amount of a Pyrrolopyrimidine Compound, and methods for treating or preventing breast cancer, more particularly triple negative breast cancer, comprising administering an effective amount of such Pyrrolopyrimidine Compounds to a subject in need thereof.
    Type: Application
    Filed: January 15, 2014
    Publication date: July 17, 2014
    Applicant: Signal Pharmaceutical LLC
    Inventors: Andrew Antony Calabrese, Brandon Jeffy, Dale Robinson, Dan Zhu, Dehua Huang, Jan Elsner, John Boylan, Lida Tehrani, Mark A. Nagy, Mehran Fallah Moghaddam, Raj Kumar Raheja, Paul Erdman, Rama K. Narla, Roy L. Harris, Tam Minh Tran, Jennifer Riggs, Yuhong Ning
  • Publication number: 20140200206
    Abstract: Provided herein are Pyrrolopyrimidine Compounds having the following structure: wherein R1, R2, R3, and L are as defined herein, compositions comprising an effective amount of a Pyrrolopyrimidine Compound, and methods for treating or preventing breast cancer, more particularly triple negative breast cancer, comprising administering an effective amount of such Pyrrolopyrimidine Compounds to a subject in need thereof.
    Type: Application
    Filed: January 15, 2014
    Publication date: July 17, 2014
    Applicant: Signal Pharmaceutical LLC
    Inventors: Andrew Antony Calabrese, Brandon Jeffy, Dale Robinson, Dan Zhu, Dehua Huang, Jan Elsner, John Boylan, Lida Tehrani, Mark A. Nagy, Mehran Fallah Moghaddam, Raj Kumar Raheja, Paul Erdman, Rama K. Narla, Roy L. Harris, Tam Minh Tran, Jennifer Riggs, Yuhong Ning
  • Publication number: 20140113904
    Abstract: Provided herein are methods for treating or preventing prostate cancer, comprising administering an effective amount of a TOR kinase inhibitor to a patient having prostate cancer.
    Type: Application
    Filed: October 17, 2013
    Publication date: April 24, 2014
    Applicant: SIGNAL PHARMACEUTICALS, LLC
    Inventors: Deborah Mortensen, Heather Raymon, Rama K. Narla, Kristen Mae Hege, Kimberly Elizabeth Fultz, Toshiya Tsuji
  • Publication number: 20130245027
    Abstract: Provided herein are methods for treating or preventing triple negative breast cancer or hormone receptor positive breast cancer, comprising administering an effective amount of a TOR kinase inhibitor to a patient having triple negative breast cancer or hormone receptor positive breast cancer.
    Type: Application
    Filed: March 14, 2013
    Publication date: September 19, 2013
    Applicant: SIGNAL PHARMACEUTICALS, LLC
    Inventors: Shuichan Xu, Kristen Mae Hege, Heather Raymon, Rama K. Narla
  • Patent number: 8507492
    Abstract: Provided herein are Heteroaryl Compounds having the following structure: wherein R1-R4 are as defined herein, compositions comprising an effective amount of a Heteroaryl Compound and methods for treating or preventing cancer, inflammatory conditions, immunological conditions, neurodegenerative diseases, diabetes, obesity, neurological disorders, age-related diseases, or cardiovascular conditions, comprising administering an effective amount of a Heteroaryl Compound to a patient in need thereof.
    Type: Grant
    Filed: November 14, 2011
    Date of Patent: August 13, 2013
    Assignee: Signal Pharmaceuticals, LLC
    Inventors: Sophie Perrin-Ninkovic, Roy L. Harris, John Sapienza, Graziella Shevlin, Patrick Papa, Branden Lee, Garrick Packard, Lida Tehrani, Jingjing Zhao, Jennifer Riggs, Jason Parnes, Deborah Mortensen, Weiming Xu, Loui Madakamutil, Kimberly Fultz, Rama K. Narla, Sabita Sankar, Jan Elsner
  • Patent number: 8492381
    Abstract: Provided herein are Heteroaryl Compounds having the following structure: wherein R1-R4 are as defined herein, compositions comprising an effective amount of a Heteroaryl Compound and methods for treating or preventing cancer, inflammatory conditions, immunological conditions, neurodegenerative diseases, diabetes, obesity, neurological disorders, age-related diseases, or cardiovascular conditions, comprising administering an effective amount of a Heteroaryl Compound to a patient in need thereof.
    Type: Grant
    Filed: November 14, 2011
    Date of Patent: July 23, 2013
    Assignee: Signal Pharmaceuticals, LLC
    Inventors: Sophie Perrin-Ninkovic, Roy L. Harris, John Sapienza, Graziella Shevlin, Patrick Papa, Branden Lee, Garrick Packard, Lida Tehrani, Jingjing Zhao, Jennifer Riggs, Jason Parnes, Deborah Mortensen, Weiming Xu, Loui Madakamutil, Kimberly Fultz, Rama K. Narla, Sabita Sankar, Jan Elsner
  • Publication number: 20120071658
    Abstract: Provided herein are Heteroaryl Compounds having the following structure: wherein R1-R4 are as defined herein, compositions comprising an effective amount of a Heteroaryl Compound and methods for treating or preventing cancer, inflammatory conditions, immunological conditions, neurodegenerative diseases, diabetes, obesity, neurological disorders, age-related diseases, or cardiovascular conditions, comprising administering an effective amount of a Heteroaryl Compound to a patient in need thereof.
    Type: Application
    Filed: November 14, 2011
    Publication date: March 22, 2012
    Inventors: Sophie Perrin-Ninkovic, Roy L. Harris, John Sapienza, Graziella Shevlin, Patrick Papa, Branden Lee, Garrick Packard, Lida Tehrani, Jingjing Zhao, Jennifer Riggs, Jason Parnes, Deborah Mortensen, Weiming Xu, Loui Madakamutil, Kimberly Fultz, Rama K. Narla, Sabita Sankar, Jan Elsner
  • Publication number: 20120059164
    Abstract: Provided herein are Heteroaryl Compounds having the following structure: wherein R1-R4 are as defined herein, compositions comprising an effective amount of a Heteroaryl Compound and methods for treating or preventing cancer, inflammatory conditions, immunological conditions, neurodegenerative diseases, diabetes, obesity, neurological disorders, age-related diseases, or cardiovascular conditions, comprising administering an effective amount of a Heteroaryl Compound to a patient in need thereof.
    Type: Application
    Filed: November 14, 2011
    Publication date: March 8, 2012
    Inventors: Sophie Perrin-Ninkovic, Roy L. Harris, John Sapienza, Graziella Shevlin, Patrick Papa, Branden Lee, Garrick Packard, Lida Tehrani, Jingjing Zhao, Jennifer Riggs, Jason Parnes, Deborah Mortensen, Weiming Xu, Loui Madakamutil, Kimberly Fultz, Rama K. Narla, Sabita Sankar, Jan Elsner
  • Patent number: 8110578
    Abstract: Provided herein are Heteroaryl Compounds having the following structure: wherein R1-R4 are as defined herein, compositions comprising an effective amount of a Heteroaryl Compound and methods for treating or preventing cancer, inflammatory conditions, immunological conditions, neurodegenerative diseases, diabetes, obesity, neurological disorders, age-related diseases, or cardiovascular conditions, comprising administering an effective amount of a Heteroaryl Compound to a patient in need thereof.
    Type: Grant
    Filed: October 26, 2009
    Date of Patent: February 7, 2012
    Assignee: Signal Pharmaceuticals, LLC
    Inventors: Sophie Perrin-Ninkovic, Roy L. Harris, John Sapienza, Graziella Shevlin, Patrick Papa, Branden Lee, Garrick Packard, Lida Tehrani, Jingjing Zhao, Jennifer Riggs, Jason Parnes, Deborah Mortensen, Weiming Xu, Loui Madakamutil, Kimberly Fultz, Rama K. Narla, Sabita Sankar, Jan Elsner
  • Publication number: 20100216781
    Abstract: Provided herein are Heteroaryl Compounds having the following structure: wherein R1-R4 are as defined herein, compositions comprising an effective amount of a Heteroaryl Compound and methods for treating or preventing cancer, inflammatory conditions, immunological conditions, neurodegenerative diseases, diabetes, obesity, neurological disorders, age-related diseases, or cardiovascular conditions, comprising administering an effective amount of a Heteroaryl Compound to a patient in need thereof.
    Type: Application
    Filed: October 26, 2009
    Publication date: August 26, 2010
    Inventors: Sophie Perrin-Ninkovic, Roy L. Harris, John Sapienza, Graziella Shevlin, Patrick Papa, Branden Lee, Garrick Packard, Lida Tehrani, Jingjing Zhao, Jennifer Riggs, Jason Parnes, Deborah Mortensen, Weiming Xu, Loui Madakamutil, Kimberly Fultz, Rama K. Narla, Sabita Sankar, Jan Elsner
  • Publication number: 20090099178
    Abstract: This invention is directed to Indazole Compounds or pharmaceutically acceptable salts, solvates and hydrates thereof. The Indazole Compounds have utility in the treatment or prevention of a wide range of diseases and disorders that are responsive to the inhibition, modulation or regulation of kinases, such as inflammatory diseases, abnormal angiogenesis and diseases related thereto, cancer, atherosclerosis, a cardiovascular disease, a renal disease, an autoimmune condition, macular degeneration, disease-related wasting, an asbestos-related condition, pulmonary hypertension, diabetes, obesity, pain and others. Thus, methods of treating or preventing such diseases and disorders are also disclosed, as are pharmaceutical compositions comprising one or more of the Indazole Compounds. This invention is based, in part, upon the discovery of a novel class of 5-triazolyl substituted indazole molecules that have potent activity with respect to the modulation of protein kinases.
    Type: Application
    Filed: December 19, 2008
    Publication date: April 16, 2009
    Inventors: Shripad S. Bhagwat, Yoshitaka Satoh, Steven T. Sakata, Chris A. Buhr, Ronald Albers, John Sapienza, Veronique Plantevin, Qi Chao, Kiran Sahasrabudhe, Rachel Stengone, Rama K. Narla
  • Patent number: 6797721
    Abstract: Synthetic Phorboxazole A and derivatives thereof for the treatment of cancer, including inhibition of cancer cell growth, induction of apoptosis, and inhibition of metastises.
    Type: Grant
    Filed: May 14, 2002
    Date of Patent: September 28, 2004
    Assignees: Parker Hughes Institute, Regents of the University of Minnesota
    Inventors: Fatih M. Uckun, Rama K. Narla, Craig Forsyth, Chi Sing Lee, Feryan Ahmed, Russell Drew Cink
  • Patent number: 6794541
    Abstract: This invention provides combinatorial chemistry libraries containing thiourea and urea compounds. In addition, the invention relates to methods for constructing combinatorial chemistry libraries containing thiourea and urea compounds. Furthermore, this invention relates to methods for the identification of bioactive thiourea and urea compounds as well as compositions and therapeutic methods for treating cancer.
    Type: Grant
    Filed: September 19, 2001
    Date of Patent: September 21, 2004
    Assignee: Parker Hughes Institute
    Inventors: Zhaohai Zhu, Chen Mao, Rama K. Narla, Fatih M. Uckun
  • Patent number: 6737537
    Abstract: The present invention describes platinum (II) compounds and compositions useful for treating a subject with a tumor and/or inducing apoptosis in a population of cells. The present invention also describes pharmaceutical compositions containing the aforementioned inventive compound(s) in combination with a pharmaceutically acceptable carrier. Additionally, the invention further provides a method of inducing apoptosis in a population of cells and a method of treating a subject with a tumor, wherein the method comprises administering to the subject a therapeutically effective amount of the aforementioned compound(s) or composition(s).
    Type: Grant
    Filed: May 15, 2002
    Date of Patent: May 18, 2004
    Assignee: Parker Hughes Institute
    Inventors: Faith M. Uckun, Rama K. Narla
  • Publication number: 20030176410
    Abstract: The present invention describes platinum (II) compounds and compositions useful for treating a subject with a tumor and/or inducing apoptosis in a population of cells. The present invention also describes pharmaceutical compositions containing the aforementioned inventive compound(s) in combination with a pharmaceutically acceptable carrier. Additionally, the invention further provides a method of inducing apoptosis in a population of cells and a method of treating a subject with a tumor, wherein the method comprises administering to the subject a therapeutically effective amount of the aforementioned compound(s) or composition(s).
    Type: Application
    Filed: May 15, 2002
    Publication date: September 18, 2003
    Applicant: Parker Hughes Institute
    Inventors: Fatih M. Uckun, Rama K. Narla
  • Publication number: 20030125366
    Abstract: Synthetic Phorboxazole A and derivatives thereof for the treatment of cancer, including inhibition of cancer cell growth, induction of apoptosis, and inhibition of metastises.
    Type: Application
    Filed: May 14, 2002
    Publication date: July 3, 2003
    Applicant: Parker Hughes Institute
    Inventors: Fatih M. Uckun, Rama K. Narla, Craig Forsyth, Chi Sing Lee, Feryan Ahmed, Russel Drew Cink
  • Publication number: 20020103380
    Abstract: This invention provides combinatorial chemistry libraries containing thiourea and urea compounds. In addition, the invention relates to methods for constructing combinatorial chemistry libraries containing thiourea and urea compounds. Furthermore, this invention relates to methods for the identification of bioactive thiourea and urea compounds as well as compositions and therapeutic methods for treating cancer.
    Type: Application
    Filed: September 19, 2001
    Publication date: August 1, 2002
    Applicant: Parker Hughes Institute
    Inventors: Zhaohai Zhu, Chen Mao, Rama K. Narla, Fatih M. Uckun